AskBiography Logo   Latest News  Follow Us on Twitter  Follow Us on Google Buzz  Became Fan - Facebook  Subscribe to RSSRSS   Bookmark and Share

Celgene

Celgene
Company nameCelgene Corporation
Company typePublic
IndustryPharmaceutical
Founded1986
HeadquartersSummit, New Jersey, U.S.
Key peopleSol J. Barer (Chairman)
Robert J. Hugin (CEO)
ProductsTHALOMID
REVLIMID
Revenue(+) US$ 3.626 billion (2010)
Operating income(+) US$ 989.6 million (2010)
Net income(+) US$ 880.2 million (2010)
Total assets(+) US$ 10.177 billion (2010)
Total equity(+) US$ 5.995 billion (2010)
Employees4,182 (December 2010)

     Home | Company | Celgene



Celgene Corporation (Nasdaq - CELG) is a manufacturer of drug therapies for cancer and inflammatory disorders. It is incorporated in Delaware and headquartered in Summit, New Jersey. The company's major products are THALOMID (thalidomide), which is approved for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum ("ENL"), as well as in combination with dexamethasone for patients with newly diagnosed multiple myeloma, and REVLIMID (lenalidomide), for which the company has received FDA and EMEA approval in combination with dexamethasone for the treatment of multiple myeloma patients who have received at least one prior therapy. REVLIMID is also approved in the United States for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Both THALOMID and REVLIMID are sold through proprietary risk-management distribution programs to ensure safe and appropriate use of these pharmaceuticals. Celgene also receives royalties from Novartis Pharma AG on sales of the entire RITALIN family of drugs, which are widely used to treat Attention Deficit Hyperactivity Disorder (ADHD).

Celgene Cellular Therapeutics, a subsidiary, is a public cord blood bank.

Celgene Video

www.igotcramered.com celg hans turbo chef Jim Cramer ISRG natural celgene cnbc
1.58 min. | 5.0 user rating		 A panel featuring several executives in the biotech field shares insights on investing in healthcare technologies. Panelists include: Bob Hariri, CEO of Celgene Cellular Therapeutics; Jonathan Fleming, Managing General Partner of Oxford Bioscience Partners; Hal Werner, General Partner and Founder of Healthcare Ventures LLC; Ed Zschau (moderator), Visiting Professor of High-Technology Entrepreneurship, Princeton University This event was co-sponsored by Princeton University's Keller Center for Innovation in Engineering Education, the Jumpstart New Jersey Angel Network, and Drinker Biddle & Reath, LLP. www.princeton.edu www.jumpstartnj.com
82.57 min. | 0 user rating		 Celgene's flagship products Thalomid and Revlimid are versions of the infamous thalidomide, the morning sickness remedy pulled from shelves in the 1960s after it was linked to birth defects. Both drugs are approved in the US and Europe as a treatment for multiple myeloma (bone marrow cancer). Revlimid also is used to treat a malignant blood disease called MDS. Celgene sells each drug under strict risk management plans that ensure they are safely administered. The firm has other drugs in development that combat inflammatory diseases and cancer. Fidelity Management and Research and Janus Capital Management combined hold about 15% of the company's shares.
1.05 min. | 5.0 user rating		 6/30/2010-Biopharmaceutical firm Celgene Corporation (NASDAQ:CELG) said Wednesday that it would buy Abraxis BioScience in a cash and stock deal valued at approximately $2.9 billion. Celgene is acquiring the firm in order to gain rights for its oncology treatments, including Abraxane, for patients that suffer from breast cancer. The deal implies a price of $71.93 per Abraxis share and Celgene expects the deal to close in the fourth quarter. Celgene is offering $58 in cash and 0.2617 of a Celgene share for each Abraxis share. The deal represents a 17% premium over Abraxis' Tuesday close of $61.31. The deal also includes certain delayed cash payments of a total of $650 million upon reception of various regulatory approvals, and potential cash royalty payments.
1.12 min. | 5.0 user rating
9.95 min. | 0 user rating
SmarTrend 's Biotechnology Industry consists of companies engaged in the research and development of new drugs, medical devices and procedures. The industry includes the manufacturing and marketing of drugs as a result of direct research and development. Choose from a wide selection of stocks to build up a Biotechnology Stock List to track. The top 5 stocks that are the most representative stocks in the industry based on market cap are: Amgen; Celgene; Genzyme; Gilead Sciences; and Biogen Idec. For more on the top 5 stocks in the Biotechnology industry, see their respective company profiles on our youtube channel, trade the trend.
0.73 min. | 5.0 user rating		 On September 23, just 2 weeks after finishing my ride from Calgary to Toronto, I set out with Kevin Leshuk from Celgene Canada to ride from Toronto out to Celgene's offices in Oakville. Celgene was gracious enough to donate $10000 to our fund raiser and provide a fantastic day of biking, good food, and amazing people. We had a film crew capturing the day and this video shows some of the highlights of an amazing way to tie up one of the greatest experiences of my life. prairiepedal.blogspot.com
2.43 min. | 0 user rating		 You are Watching: ASCO 2008, Focus on Celgene with Mike King. Celgene in a Post-ASCO review, reveals positive data. Mike King discusses the multiple myeloma survival data and its impact on Revlimid. Mike compares Celgene's Revlimid and (Takeda's) Millenium's Velcade. Is complete response the best predictor of outcome? How do the other parameters of the studies come into play? Mike gives us a projection for the sales of Revlimid and a price target for Celgene at $72. Last he touches upon the question of Celgene's acquisition. Would it make any sense? Update: Celgenes stock (CELG) reached $72.63 on July 21st, from $63.35 on the day of this interview. This interview was conducted at the NASDAQ Marketsite, on June 5th, 2008, in New York City, on the occasion of the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO). Featuring: * Michael King, Director of Research, Rodman & Renshaw * Daniel Teper, Managing Director of Bionest Partners, and Founder & Chairman of BioBusiness.TV DISCLAIMER: BIOBUSINESS.TV IS AN INDEPENDENT MEDIA, AND A PLATFORM FOR THE EXCHANGE OF IDEAS AND OPINIONS. BIOBUSINESS.TV STRIVES TO ENHANCE THE QUALITY AND ACCESSIBILITY OF INDUSTRY DATA, AND TO DELIVER INFORMATION THAT INVESTORS AND EXECUTIVES CAN RELY UPON TO MAKE SOUND, INFORMED FINANCIAL AND MANAGERIAL DECISIONS. VIEWERS SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH <b>...</b>
1.28 min. | 0 user rating		 You are Watching: Oncology Battlegrounds: Celgene vs. Millenium, with Charles Duncan. The long running face off between Celgene's Revilimid and Millenium's Velcade intensifies with the latest clinical data releases. Charles Duncan, is bullish on Revlimid, he tells us why. Charles looks at the impact of Takeda's new ownership of Millenium on its management and competitivity vs. Celgene. Charles also comments on the JNJ / Takeda relationship. This interview was conducted at the NASDAQ Marketsite, on June 26th, 2008, in New York City. Featuring: * Charles Duncan, Managing Director and Senior Biotechnology Analyst, JMP Securities * Daniel Teper, Managing Director atBionest Partners, and Founder & Chairman of BioBusiness.TV DISCLAIMER: BIOBUSINESS.TV IS AN INDEPENDENT MEDIA, AND A PLATFORM FOR THE EXCHANGE OF IDEAS AND OPINIONS. BIOBUSINESS.TV STRIVES TO ENHANCE THE QUALITY AND ACCESSIBILITY OF INDUSTRY DATA, AND TO DELIVER INFORMATION THAT INVESTORS AND EXECUTIVES CAN RELY UPON TO MAKE SOUND, INFORMED FINANCIAL AND MANAGERIAL DECISIONS. VIEWERS SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK.
1.40 min. | 0 user rating		 The Southern California Biomedical Council is a nonprofit, member-supported trade association that supports and promotes life-science research, development, manufacturing, job creation and overall economic growth in the six counties of the Greater Los Angeles region (Los Angeles, Orange, Ventura, Santa Barbara, Riverside and San Bernardino Counties). The Councils programs help local firms gain access to capital, potential partners and business support services. The annual SoCalBio Investor & Partnership Conference has grown to become the region's premiere showcase for emerging life-science companies and technologies. SoCalBio also promotes technology transfer and workforce training, while informing policy makers and the public at-large about the benefits of the regions life-science industry. SoCalBio is open to membership by firms and organizations engaged in life-science technology development and commercialization. More information is available at www.socalbio.org" Phone 213-236-4890 -- email: scbc@socalbio.org This video was produced by Marshall Thompson, Multimedia/Multicultural video producer, marshall@prvideo.tv, 310-403-2507
12.30 min. | 0 user rating

Latest News : Celgene : Tweet this RSS

Want to Celgene latest news on your twitter account???   sign in with twitter
Celgene     sign in with twitter   ||  Company     sign in with twitter   ||  Economy     sign in with twitter
Celgene Among Gerald L. Ray & Associates' Top 5 Stocks - cbl - Citybizlist (press release) Tweet this news
Citybizlist (press release)--(NYSE: LUV), $13.23 million; Summit, NJ-based -Celgene- Corp. (Nasdaq: CELG), which makes drugs to treat cancer and immune-inflammatory diseases, $8.9 million ... - Date : Wed, 27 Oct 2010 15:37:37 GMT+00:00
Biolex's Locteron has promising Phase IIB results; Celgene exceeds earnings ... - FierceBiotech Tweet this news
FierceBiotech--Biolex release > -Celgene- posted higher than expected Q3 earnings ($910.1 million), including higher sales ($641.3 million) for its multiple myeloma drug ... - Date : Thu, 28 Oct 2010 16:31:33 GMT+00:00
Earnings Preview: Celgene - Seeking Alpha Tweet this news
Seeking Alpha---Celgene- (CELG) is expected to report Q3 earnings Thursday, October 28 before market open, with a conference call scheduled for 9 am ET. ... - Date : Wed, 27 Oct 2010 18:45:21 GMT+00:00
Abraxis stockholders vote for Celgene acquisition - BusinessWeek Tweet this news
BusinessWeek---Celgene- Corp. and Abraxis Bioscience Inc. said Wednesday that Abraxis' stockholders voted in favor of its acquisition by -Celgene-. -Celgene- said in June that ... - Date : Thu, 14 Oct 2010 04:28:42 GMT+00:00
Celgene Corp. Reports Operating Results (10-Q) - GuruFocus.com Tweet this news
GuruFocus.com---Celgene- Corp. has a market cap of $28.07 billion; its shares were traded at around $61.9 with a P/E ratio of 27.5 and P/S ratio of 10.4. ... - Date : Tue, 02 Nov 2010 11:29:31 GMT+00:00
Celgene Q3 2010 Earnings Call Transcript - TheStreet.com Tweet this news
TheStreet.com--By Seeking Alpha 10/28/10 - 03:05 PM EDT Good day, ladies and gentlemen, and welcome to -Celgene's- Third Quarter Conference Call. ... - Date : Thu, 28 Oct 2010 19:26:33 GMT+00:00
Celgene reports 30 percent boost in earnings - The Star-Ledger - NJ.com Tweet this news
The Star-Ledger - NJ.com--During a conference call with industry analysts yesterday, -Celgene- provided highlights of its business performance. Profit: Quarterly earnings increased to ... - Date : Fri, 29 Oct 2010 13:33:45 GMT+00:00
Pfizer talks deal strategy as analysts buzz about Sanofi's next move - FierceBiotech Tweet this news
FierceBiotech--And then the wire service speculates about who would make a better target for Sanofi if Genzyme proves too pricey: Gilead, Biogen Idec, -Celgene- and Amgen ... - Date : Wed, 04 Aug 2010 12:25:09 GMT+00:00
Celgene Corporation to Announce Second Quarter 2010 Results on July 29, 2010 - MarketWatch (press release) Tweet this news
MarketWatch (press release)--The webcast will be available in the investor relations section of the company's Web site at www.-celgene-.com. -Celgene- Corporation, headquartered in Summit, ... - Date : Mon, 19 Jul 2010 20:36:58 GMT+00:00
Citi analyst makes Celgene, Human Genome top picks - BusinessWeek Tweet this news
BusinessWeek--A Citi analyst named -Celgene- and Human Genome Sciences his top stock picks Monday, citing a mix of positive items on the balance sheet and product potential ... - Date : Tue, 20 Jul 2010 04:24:00 GMT+00:00

Product Portfolio
Brand Name Drug Name(s) Indication Date Approved (USA) Partner
Vidaza azacitidine treatment of patients with myelodysplastic syndromes (MDS) 05-19-2004
Revlimid lenalidomide transfusion dependent anemia due to low or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5 q cytogenetic abnormality with or without additional cytogenetic abnormalities 12-27-2005
Revlimid lenalidomide (in combination with dexamethasone) treatment of multiple myeloma patients who have received at least one prior therapy 06-29-2006
Thalomid thalidomide acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL) and maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrences 07-16-1998
Thalomid thalidomide (in combination with dexamethasone) treatment of patients with newly diagnosed multiple myeloma 05-25-2006 GlaxoSmithKline
Alkeran melphalan palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary 01-17-1964 GlaxoSmithKline
Alkeran melphalan hydrochloride the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate 11-18-1992 GlaxoSmithKline
Focalin dexmethlyphenidate hydrochloride attention deficit hyperactivity disorder (ADHD) in children and adolescents 11-13-2001 Novartis
Focalin XR dexmethlyphenidate hydrochloride attention deficit hyperactivity disorder (ADHD) in children, adolescents and adults 05-26-2005 Novartis

Companies of the NASDAQ-100 index

Activision Blizzard * Adobe * Akamai * Altera * Amazon.com * Amgen * Apollo Group * Apple * Applied Materials * Autodesk * ADP * Baidu * Bed Bath & Beyond * Biogen Idec * BMC Software * Broadcom * C.H. Robinson * CA, Inc. * Celgene * Cephalon * Cerner * Check Point * Cintas * Cisco * Citrix * Cognizant * Comcast * Costco * Dell * Dentsply * DirecTV * Dish Network * eBay * Electronic Arts * Expedia * Expeditors International * Express Scripts * Fastenal * First Solar * Fiserv * Flextronics * FLIR Systems * Foster Wheeler * Garmin * Genzyme * Gilead Sciences * Google * Henry Schein * Hologic * Illumina * Infosys * Intel * Intuit * Intuitive Surgical * J.B. Hunt * Joy Global * KLA-Tencor * Lam Research * Liberty Media * Life Technologies * Linear Technology * Logitech * Marvell * Mattel * Maxim Integrated Products * Microchip Technology * Microsoft * Millicom * Mylan * NetApp * News Corporation * NII * Nvidia * O'Reilly Automotive * Oracle * Paccar * Patterson Companies * Paychex * Priceline.com * Qiagen * Qualcomm * Research In Motion * Ross Stores * SanDisk * Seagate * Sears * Sigma-Aldrich * Staples * Starbucks * Stericycle * Symantec * Teva Pharmaceutical * Urban Outfitters * VeriSign * Vertex Pharmaceuticals * Virgin Media * Vodafone * Warner Chilcott * Wynn Resorts * Xilinx * Yahoo!



Privacy | Sitemap | Micra Hosting | USA Yellow Pages